Trial intelligence / Profile preview

Early vs standard extended adjuvant neratinib in HER2-positive, hormone receptor-negative high-risk breast cancer

ChiCTR2500106219Phase 4Not yet recruiting

Sponsor

Shandong First Medical University

Start

Jul 2025

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1